Q1 Earnings Forecast for AVBP Issued By B. Riley

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of ArriVent BioPharma in a research report issued on Wednesday, March 19th. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.70) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. B. Riley also issued estimates for ArriVent BioPharma's Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.30) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($3.52) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at $0.40 EPS.

A number of other brokerages also recently commented on AVBP. HC Wainwright reaffirmed a "buy" rating and issued a $39.00 price target on shares of ArriVent BioPharma in a report on Friday, March 7th. Guggenheim initiated coverage on ArriVent BioPharma in a report on Monday, March 10th. They issued a "buy" rating and a $45.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $39.00.

ArriVent BioPharma Stock Up 1.6 %

ArriVent BioPharma stock traded up $0.29 during midday trading on Monday, reaching $18.57. 166,032 shares of the stock traded hands, compared to its average volume of 159,530. The stock has a market cap of $631.68 million, a P/E ratio of -7.23 and a beta of 1.00. The stock's fifty day moving average is $24.57 and its 200-day moving average is $26.56. ArriVent BioPharma has a 12 month low of $14.35 and a 12 month high of $36.37.

Remove Ads

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.18.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC boosted its holdings in ArriVent BioPharma by 21.7% during the 4th quarter. Suvretta Capital Management LLC now owns 2,246,000 shares of the company's stock valued at $59,833,000 after acquiring an additional 400,838 shares during the period. FMR LLC lifted its position in shares of ArriVent BioPharma by 8.7% during the third quarter. FMR LLC now owns 2,119,695 shares of the company's stock worth $49,813,000 after purchasing an additional 169,514 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in shares of ArriVent BioPharma by 4.2% during the fourth quarter. Octagon Capital Advisors LP now owns 2,059,387 shares of the company's stock valued at $54,862,000 after purchasing an additional 83,000 shares during the period. Infinitum Asset Management LLC bought a new position in shares of ArriVent BioPharma in the fourth quarter worth about $43,794,000. Finally, Novo Holdings A S increased its stake in ArriVent BioPharma by 1.0% in the 4th quarter. Novo Holdings A S now owns 1,520,627 shares of the company's stock worth $40,510,000 after buying an additional 15,312 shares during the period. Institutional investors own 9.48% of the company's stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.